Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.52 |
| ▸ | MLYCD | O95822 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4552782 | 0.95 | ROCK2 (0.51) | ROCK2ROCK1TDP1HDAC6MLYCD | |
| SCHEMBL4553284 | 0.92 | ROCK2 (0.50) | ROCK2ROCK1TDP1MMP13 | |
| SCHEMBL14425153 | 0.87 | SMYD3 (0.49) | ROCK2ROCK1 | |
| SCHEMBL13373545 | 0.85 | EGLN1 (0.47) | ROCK2ROCK1 | |
| SCHEMBL10722498 | 0.79 | HDAC6 (0.77) | TDP1HDAC6MLYCDMMP13MEN1 | |
| SCHEMBL2917118 | 0.79 | TDP1 (0.68) | TDP1HDAC6MLYCDMMP13MEN1 | |
| SCHEMBL5083134 | 0.78 | HDAC6 (0.55) | ROCK2TDP1HDAC6MLYCDMMP13 | |
| SCHEMBL5525010 | 0.78 | ACACB (0.48) | ROCK2ROCK1 | |
| SCHEMBL5525008 | 0.78 | ACACB (0.48) | ROCK2ROCK1 | |
| SCHEMBL30635470 | 0.76 | HDAC6 (0.52) | ROCK2TDP1HDAC6MLYCDMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | ROCK2 4342/4885ROCK1 4527/4885TDP1 3631/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | ROCK2 4342/4885ROCK1 4527/4885TDP1 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.